Advertisement
The presentation entitled: "Celgosivir (MX-3253) Resistance Profile UsingBovine Viral Diarrhea Virus" will be made today from 5:30pm to 8:00pm, Glasgowtime (9:30am - noon Pacific Time) by Dominique Dugourd, Ph.D., MicrobiologyGroup Leader at MIGENIX. A copy of the presentation and the related Abstract(abstract P-223) will be available at www.migenix.com at the start of thepresentation. The conference covers a broad spectrum of topics from molecularvirology to new antiviral therapies and attracts major scientists and thoughtleaders in the field.
Advertisement
Jacob Clement, Ph.D., CSO at MIGENIX and coauthor of the paper, believesthat the results of these laboratory studies with the accepted HCV surrogatevirus BVDV, indicate that the emergence of resistance in a clinical setting isunlikely to occur. "We were unable to induce viral resistance to celgosivireven after repeated exposure to high levels of the agent in a system whichrapidly develops relatively high levels of resistance to other direct actingantivirals."
About Celgosivir (MX-3253)
Celgosivir is an oral alpha-glucosidase I inhibitor and is currently theonly anti-HCV drug in clinical development that acts on host-directedglycosylation. In preclinical studies, celgosivir has shown excellent in vitrosynergy with various interferons in the clinic or in development includingPegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or withoutribavirin) and other drugs in development for the treatment of HCV (e.g.polymerase inhibitors) and therefore has the potential to be included as partof multiple combination approaches to improve efficacy in anti-HCV therapy.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enrichinglife by developing and commercializing drugs primarily in the area ofinfectious diseases. The Company's clinical programs include drug candidatesfor the treatment of chronic hepatitis C infections (Phase II andpreclinical), the prevention of catheter-related infections (Phase III) andthe treatment of dermatological diseases (Phase II). MIGENIX is headquarteredin Vancouver, British Columbia, Canada with US operations in San Diego,California. Additional information can be found at www.migenix.com.
This news release contains forward-looking statements within the meaningof the United States Private Securities Litigation Reform Act of 1995, andforward-looking information within the meaning of applicable securities lawsin Canada, (collectively referred to as "forward-looking statements").Statements, other than statements of historical fact, are forward-lookingstatements. By their nature, forward-looking statements involve numerousassumptions, known and unknown risks and uncertainties, both general andspecific, that contribute to the possibility that the predictions, forecasts,projections and other things contemplated by the forward-looking statementswill not occur.
Although our management believes that the expectations represented by suchforward-looking statements are reasonable, there is significant risk that theforward-looking statements may not be achieved, and the underlying assumptionsthereto will not prove to be accurate. Forward-looking statements in this newsrelease include, but are not limited to, statements concerning our scientist'sexpectations that the emergence of resistance to celgosivir in a clinicalsetting is unlikely to occur
With respect to the forward-looking statements contained in this newsrelease, we have made
